FDA's 2005 NME Approvals: Agency Lags At Third Quarter Mark?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves just over half as many new molecular entities in first three quarters of 2005 as in the same period of 2004; BLA tally is well ahead of full year 2004.
You may also be interested in...
Average Approval Time Slows As FDA Clears Greater Number Of NMEs In 2004
Average time to approval was 18.7 months for a new molecular entity in 2004, versus 17.1 in 2003. FDA cleared 31 NMEs in 2004, 10 more than the prior year. CDER appears to be setting a strong precedent with its first year of therapeutic biologic reviews.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.